SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synaptogenix, Inc. on September 9, 2024, covering an event that occurred on September 3, 2024. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. The filing addresses Item 5.03 regarding amendments to the Certificate of Designations for its Series B Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a current event disclosure and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the extension of the maturity date for the Company's Series B Convertible Preferred Stock. Previously, the maturity date was set for August 31, 2024. Pursuant to a Certificate of Amendment filed on September 3, 2024, the maturity date has been extended to September 9, 2024. This extension is subject to further extension pursuant to the terms of the Certificate of Designations.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard incorporation by reference of the Amendment text. The document notes that the description of the Amendment is qualified in its entirety by reference to the full text filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the full terms of the Series B Convertible Preferred Stock by reviewing Exhibit 3.1 (Certificate of Amendment) attached to the filing.
- Confirm whether the maturity date extension to September 9, 2024, triggers any immediate conversion rights or payment obligations.
- Check for any subsequent filings regarding further extensions of the Preferred Shares beyond September 9, 2024.
- Note the discrepancy between the request metadata company name ("TAO Synergies Inc.") and the actual registrant in the filing text ("Synaptogenix, Inc.").